Transdermal contraceptive hormones delivery
Inventors
Rossi, Thomas M. • Foegh, Marie • Kydonieus, Agis
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9775817-B2
Publication Date
2017-10-03
Expiration Date
Abstract
Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.
Core Innovation
A method of preventing pregnancy in a woman is provided that uses a five-week treatment cycle having a four-week treatment interval and a one-week rest interval. During the treatment interval, a contraceptively effective amount of a progestin and an estrogen is transdermally administered by successive weekly applications of four transdermal hormone delivery treatment interval devices, one for each week of the treatment interval.
During the rest interval, low dose progestin and low dose estrogen are transdermally administered throughout by application of a low dose transdermal hormone delivery device during the rest interval. The rest interval device delivers between 25% and 75% of the amount of progestin and between 25% and 75% of the amount of estrogen as delivered by each treatment interval device, and the woman experiences menstruation during the rest interval.
Claims Coverage
1 independent claim is provided, reciting a transdermal contraceptive method with a four-week treatment interval followed by a one-week rest interval, including specific quantitative relationships for hormone delivery during the rest interval.
Weekly successive transdermal treatment interval with progestin and estrogen over four weeks
Transdermally administering a contraceptively effective amount of a progestin and an estrogen during a four-week treatment interval by successive weekly applications of four transdermal hormone delivery treatment interval devices, one for each week of the treatment interval.
Low-dose transdermal rest interval delivering 25% to 75% of treatment-interval hormone amounts
Transdermally administering low dose progestin and low dose estrogen throughout a one-week rest interval by application of a low dose transdermal hormone delivery device, wherein the rest interval device delivers between 25% and 75% of the amount of progestin and between 25% and 75% of the amount of estrogen as delivered by each treatment interval device, with menstruation during the rest interval.
The claim coverage centers on a transdermal contraceptive regimen that splits administration into four weekly treatment devices delivering a contraceptively effective amount, and a one-week rest interval device delivering reduced hormone amounts (25% to 75%) relative to the treatment interval devices while maintaining menstruation during the rest interval.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?